Inovio Pharmaceuticals Inc

GBM

Company Profile

  • Business description

    Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.

  • Contact

    660 West Germantown Pike
    Suite 110
    Plymouth MeetingPA19462
    USA

    T: +1 267 440-4200

    E: [email protected]

    https://www.inovio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    112

Stocks News & Analysis

stocks

SpaceX is scaling AI infrastructure on earth, data centers in space might be next

Our view on the first results as a publicly traded company.
stocks

Investors too optimistic about overvalued ASX share

Upgraded first-half revenue guidance at the upper end of the previously announced range.
stocks

Restructuring at big four bank

Job cuts create capacity to invest as revenue growth slows.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,917.1039.50-0.44%
CAC 407,841.8379.85-1.01%
DAX 4025,517.12127.92-0.50%
Dow JONES (US)52,856.09360.210.69%
FTSE 10010,740.4312.45-0.12%
HKSE22,934.68717.19-3.03%
NASDAQ26,702.86278.041.05%
Nikkei 22562,907.841,713.40-2.65%
NZX 50 Index13,746.8414.45-0.11%
S&P 5007,757.170.000.00%
S&P/ASX 2008,793.2038.10-0.43%
SSE Composite Index3,658.0355.00-1.48%

Market Movers